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Cancer is a major European public health issue and represents the second most important cause of death and
morbidity in Europe. Moreover, as a result of constant advances in medicine, medical technology and other
sciences, and due to improvements in economic circumstances, cancer survival rates are increasing in Europe and
prevalent cases (i.e. number of subjects who have experienced cancer) represent a growing proportion of the
population. In order to tackle cancer efficiently throughout the European Member states, the European Commission
launched the Joint Action (JA) ‘European Partnership for Action Against Cancer’ (EPAAC) facilitated by the
Community Health Programme, in September 2009. EPAAC is designed to fill a gap in cooperation, collaboration
and shared experiences for countries with similar needs and diverse experience in the area of their national cancer
control policies. Activities and studies are tackling the main challenges of cancer control in Europe as a whole and
in the Member states, including the provision of services and health system responses, human resources and
research. In contrast with previous European actions in the field of cancer, EPAAC joins different partners and
stakeholders at various levels ranging from Member states (including Iceland and Norway) and Regions to patient
representatives.
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Modern-day health systems are under enormous pres-
sure in terms of disease burden, demographic trends,
the evolving roles of citizens, patients and health profes-
sionals, political challenges and sustainable financing.
The twentieth century saw a dramatic epidemiologic
shift in Europe and in the Western world in general,
where infant mortality and deaths from communicable
diseases such as tuberculosis, polio and infectious out-
breaks were gradually overcome or controlled by effect-
ive public health policies. The most destructive diseases
in Europe today are chronic rather than acute, affecting
an ageing and predominantly urban population. Further-
more, older population is not only more susceptible to
disease (and therefore more dependent on the health
system), but also less able to contribute to already cash-
strapped governments which are the main source of
health system financing. In addition to this, with the
ageing of the population and therefore of cancer* Correspondence: marjetka.jelenc@ivz-rs.si
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reproduction in any medium, provided the orpatients, comorbidities have become much more fre-
quent and this limits the use of the existing cancer-
related guidelines or, at least, reduces their effectiveness.
The unification of Europe has brought with it both chal-
lenges such as the harmonization of European legislation
and standards, as well as opportunities in fields such as
medical and health-system research. Finally, the predom-
inance of chronic disease has made the role that citizens
and patients play in managing their own health an indis-
pensable one, while the globalized communication revo-
lution has equipped them with the tools necessary to
make their voices heard clearer than ever.
Cancer survival is increasing in Europe as a result of early
diagnosis and improved treatment [1], with the corollary
that the proportion of people in the population with a
(past) diagnosis of cancer is growing. According to the pro-
ject Surveillance of Rare Cancers in Europe (RARECARE)
estimates – based on cancer registry data – in the European
Union there were 3,566 individuals per 100,000 with a pre-
vious diagnosis of some form of cancer on 1st January 2003
equivalent to a total prevalence of nearly 17.8 million [2].
The number of prevalent cancer cases is projected toLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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cancer incidence increases, and as survival improves [3].
European Cancer Registry-based Study on Survival and
Care of Cancer Patients (EUROCARE) estimated that the
proportion of patients (diagnosed from 1988 to 1999) con-
sidered cured of their cancer (all cancers combined) varied
between 38% and 59% in women, and 21% and 47% in
men, depending on the country [4].
Cancer incidence is rising in ageing populations and
patients are increasingly informed, empowered and assert-
ive with regard to their rights and their wishes. At the same
time cancer is an umbrella term for 150 different patholo-
gies which tax financial and human resources across mul-
tiple health services, from primary prevention to palliative
care and rehabilitation. European governments are addres-
sing these challenges as they can, with greater or lesser suc-
cess, but it is apparent that effective and cost-efficient
system-wide policies for cancer control are needed more
urgently now than ever throughout the European
continent.
The cancer burden also varies quite significantly by
country, although admittedly completely accurate data
remains elusive given the differences in reporting qual-
ity. Incidence in Hungary and the Czech Republic is not-
ably higher than in the rest of the European Union,
including neighbouring countries in Eastern Europe.
Some northern European countries, such as Denmark
and The Netherlands, also stand out for their high
reported incidence.
Perhaps more illustrative of the scope of the cancer bur-
den, however, is the mortality rate in comparison to other
causes of death. Overall, it is a leading cause of death in the
European Union, second only to diseases of the cardiovas-
cular system. Moreover, in certain developed countries in-
cluding France, Spain and The Netherlands, cancer kills
more people than any other cause [5].
For many decades a lot of resources have been
invested into trying to tackle cancer and numerous pro-
jects have contributed to the fight against this disease.
Many projects are still ongoing.
The European Partnership for Action Against Cancer
(EPAAC), launched in 2009, is a three-year initiative under
the umbrella of the European Commission filling a gap in
cooperation, collaboration and shared experiences for
countries with similar needs and diverse experience in the
area of their national cancer-control policies. EPAAC
tackles the main challenges of cancer control in Europe as
a whole and in the Member states, including service
provision and health-system responses, human resources
and research [6,7].
EU public health strategy
In accordance with the Second Health Programme (SHP)
and Annual Work Plan (AWP), EPAAC JA is contributingto the protection of the health and safety of individuals
through its actions with regard to cancer, one of the eight
leading causes of mortality and morbidity from non-
communicable diseases in the World Health Organization
(WHO) European Region. Demographic ageing is a global
trend; the risk of cancer significantly increases with increas-
ing age [8]. By 2030 it is estimated that there will be 75 mil-
lion people living with cancer diagnosed within the
previous five years, and almost 20 million of them will be
living in the 53 countries of the WHO European region.
While increased longevity is a great achievement, it is also a
formidable challenge for both public and private budgets,
for public services and for older people and their families.
The expected increase in the incidence of cancer and the
associated functional frailty associated with greater age re-
quire new approaches [9].
During the United Nations Summit on Non-
Communicable Diseases (NCDs) in September 2011, the
specific target of a 25% reduction in deaths from non-
communicable disease by 2025 was set. Cancer is the
cause of a significant number of these deaths [10].
European Partnership for Action Against Cancer (EPAAC)
EPAAC embodies cooperation and collaboration in the
tackling of cancer. It includes 38 Associated Partners
from Health Authorities, Research Institutes and
Patients’Associations and over 90 collaborating partners.
The National Institute of Public Health in Slovenia has
assumed the role of leader of the EPAAC Joint Action.
Technically, EPAAC is a JA, facilitated by the Commu-
nity Health Programme and has been created to contrib-
ute to the long-term aim identified by policy makers of
reducing cancer incidence in Europe by 15% by 2020. In
order to do so, EPAAC builds upon existing knowledge
and expertise from ongoing or already completed pro-
jects. Consequently, the function of EPAAC is to inte-
grate all existing knowledge in order to identify the most
suitable practices. The specific challenge is to translate
this existing knowledge into an information-support pol-
icy throughout the Member states. The second objective
is to satisfy the need for an integrated and structured ap-
proach to tackle cancer in each Member state. For this
purpose national cancer control programmes (NCCPs)
preparation is being encouraged and NCCPs should be
implemented in every Member state by 2013. Integrated
NCCPs are public health programmes designed to en-
sure the coordinated and centrally managed implemen-
tation of evidence-based strategies for prevention, early
detection, diagnosis, treatment, palliative care, rehabilita-
tion and research for innovative solutions, as well as the
evaluation of outcomes [11]. They are designed to help
reduce the incidence, mortality and morbidity from can-
cer, as well as to improve the quality of life of cancer
patients in all Member states throughout Europe.
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tion System (ECIS) is being designed.
ECIS involves all the institutions, individuals, proce-
dures, and resources dealing with information and data
about cancer and aims to provide the necessary know-
ledge to optimize cancer control and cancer research ac-
tivities in Europe. Its main characteristics are:
 Centralized data collection and database
management.
 Network-based data analysis and data quality
control.
 Serving as a research infrastructure for the cancer
community at large.
 Sustainable funding.
To make available and disseminate cancer burden
indicators, the necessary indicators will be identified
using European Cancer Health Indicators Project
(EUROCHIP) and European Community Health Indica-
tors (ECHI) programs. Population survival and sample
data on staging and treatment acquired from cancer
registries will be available through the EUROCARE pro-
ject programme. Cancer Prevalence in Europe (EURO-
PREVAL) study will be used to provide the prevalence
data. European-funded projects, such as EUROCHIP
and Optimisation of the Use of Registries for Scientific
Excellence in Research in Europe (EUROCOURSE), have
identified the most important information needed to
support policy action on cancer control, but such infor-
mation is, however, still far from being available at a
Europe-wide level [6].
Cooperation, collaboration and shared experience are
key elements for EPAAC. In contrast to earlier projects,
EPAAC brings together technical experts, scientists, sta-
keholders, patients’ representatives and policy makers in
order to integrate all levels of expertise. In the future
EPAAC proposes to disseminate existing knowledge and
expertise as widely as possible, in order to harmonizeTable 1 The content work packages and associated strategic
Work package Main objective
Health Promotion and
Prevention
To raise awareness about cancer prevention am
Screening and Early
Diagnosis
Improvement of the implementation of the Co
Healthcare To identify, assess and exchange best-practices
Research Development of a concerted approach for coor
selected areas
Information and Data To provide an analysis of the current status of c
reorganization of the data and information flow
activities.
National Cancer Plans Preparation of guidelines for a high level standthe way cancer is dealt with and to achieve equality of
care and survival throughout Europe.
Work packages in EPAAC
In addition to work package on NCCPs, EPAAC consists
of other four core work packages: Health promotion and
prevention, Screening and early diagnosis, Healthcare,
Research and Information and data. Each work package
has its own strategic goals (Table 1).
The work package on health promotion and preven-
tion emphasizes improvement of the health status of
young people and the promotion of a healthy lifestyle
and a prevention culture – through the re-launching of
the European Week Against Cancer (EWAC).
Work package on screening and early diagnosis will
improve implementation of the Council Recommenda-
tion on Cancer Screening by alleviating key barriers, to
make screening of appropriate quality, as recommended
by the Council of the European Union, accessible to all
citizens who may benefit. Further added value will be
created by promoting synergy between cancer screening
and other areas of early detection. A network of
European Schools of Screening Management is initiated
and dedicated to capacity building for implementation
and improvement of population-based cancer screening
programmes.
Work package on healthcare focuses on examples of
good practices aimed at improving cancer care aligned
with these elements across European health services, at
national, regional and local level, which should be identi-
fied, and experiences exchanged. It has a particular focus
on new organizational perspectives in cancer care, spe-
cifically networks of cancer care at regional level and for
low frequency tumours and on issues of implementation
of evidence-based guidelines in cancer for managers and
clinicians. The key focus will be team working across
these disciplines. A training strategy to improve psycho-
social and communication skills among health care pro-
viders is being implemented.goals of the EPAAC JA
ong targeted groups in Europe
uncil Recommendation on Cancer Screening of 2 December 2003
in cancer care across EU, including the patient’s perspective
dination of one third of research from all funding sources by 2013 in
ancer information in Europe and to propose, accordingly, a strategic
, aimed at improving cancer control support and cancer research
ard NCP which includes the most significant areas
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ment of a concerted approach to achieve coordination of
one third of research from all funding sources by 2013
within selected areas of cancer research.
Special attention is given to centralising all existing
data and research concerning cancer. Efficient policy
indicators are envisaged to improve support policies
addressing active and healthy ageing, and dealing with
the impact of cancer throughout Europe. EPAAC will
bring together all the existing European partners work-
ing on cancer burden indicators to coordinate the ana-
lysis and provision of information concerning incidence,
mortality, survival and prevalence. Updated incidence
and mortality data will be made available in the frame-
work of the current activities of the International Agency
for Research on Cancer (IARC) and of the European
Network of Cancer Registries (ENCR), important co-
operators. IARC in consultation with ENCR and other
structures will be involved in the identification of a panel
of experts in population-based data analyses, projections
and forecasting [6].
Every year an Open Forum is organized to discuss the
activities within specific work packages. Open Forum is
a high-level plenary of the European network of cancer
experts, health professionals, policy makers, civil society,
patient associations, academia and provides a platform
for all the members of the partnership and other inter-
ested key stakeholders at the European level in order to
deepen their understanding of the challenges of cancer
across Member states. A dedicated website (www.epaac.eu)
centralizes all relevant information and achievements. On-
line social media are used to connect to different types of
audiences.
Where next?
By adopting the European 2020 goals, several voluntary
targets for preventing and controlling NCDs (2010–2020)
are being accepted. First, a reduction of 20% is envisaged
by improving the approach to cancer. While this may
seem overly optimistic goal, recent publications have re-
dimensioned this objective looking at the reduction in
cancer incidence by type. Cancer incidence varies greatly
across Member states but especially across types of cancer
[12]. Cancer includes many different pathologies with dra-
matic variations of incidence and prevalence in different
populations, different causalities, treatment options and
prognoses.
The most commonly diagnosed cancers in Europe are,
in order of numerical importance, breast, prostate, colo-
rectal and lung cancers and these accounted for about
half of the 3.4 million new cases in 2008. The cancer
mortality burden is dominated by the same cancer types
[12], although in a different order: lung cancer is respon-
sible for almost 20% of all cancer deaths, followed bycolorectal (12%), breast (7.5%) and pancreatic (5.4%).
The following cancers are together responsible for about
1.8%-5.1% of total cancer incidence: cancers of the pan-
creas (2.9% of all new cancers), uterus (cervix and body
of uterus combined, 4.5%), stomach (4.9%), oral cavity
and pharynx (1.8%), kidney (3.1%) and non-Hodgkin’s
lymphoma (2.7%). A few relatively uncommon cancers
are nevertheless quite significant in terms of mortality,
namely pancreatic and stomach, responsible respectively
for 5.4% and 7.2% of total cancer mortality.
The cancer burden also varies quite significantly by
country, although admittedly completely accurate data
remains elusive given the differences in reporting quality.
Perhaps more illustrative of the scope of the cancer
burden, however, is the mortality rate in comparison to
other causes of death. Overall, it is a leading cause of
death in the European Union, second only to diseases of
the cardiovascular system (Figure 1).
In reaching the set goals, national plans are a key com-
ponent for the planning and supervision of all actions
undertaken. These national plans could also serve as
support-policy development at national level in the Mem-
bers states. A specific work package has gathered data on
NCCPs throughout Europe. The analysis of these data has
been finalised and will be presented to Member states by
the end of 2012. Based upon these data and on already
existing publications concerning NCCPs, guidelines and
indicators are being identified. While there are different
ways of understanding these programmes, and all are sub-
ject to structural and contextual peculiarities intrinsic to
the diverse national settings, it is possible to sketch out
the general characteristics of these policies.
All in all, the threat that cancer represents to the
health of the population across the European Union is
too serious to ignore. Primary and secondary prevention
are essential in order to address incidence, but given that
age is the greatest risk factor of all for developing these
diseases, integrated care (including palliative and psy-
chosocial aspects) must be improved. Research and pro-
fessional training, the cornerstones of all medical
progress, must drive improvements in service delivery
across these areas. Health systems are faced with the
same challenges in tackling cancer as when addressing a
wide range of other health threats: achieving the over-
arching goals of improved general health, financial pro-
tection and response to citizen and patient needs.
Population-based information on cancer is fundamental
for cancer-control activities, as well as for health-care re-
search and, thanks to the existence of registries and to a
long tradition of epidemiological research, is much more
available than for most other diseases. In addition, very
wide and high level research activity related to cancer in-
formation and data is ongoing in Europe. The consider-
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Figure 1 Proportional mortality by broad cause of death in the EU in year 2008.
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vance in knowledge in the field of cancer epidemiology.
EPAAC work package 9 is developing proposals for the
best use of these resources, in order to overcome the
present fragmentation and duplication of effort. For this
purpose the need has been recognized for the develop-
ment of ECIS, intended to include all institutions, persons,
procedures, and resources connected with information
and data concerning cancer, and coordinated to provide
the knowledge necessary to optimize cancer-control activ-
ities. ECIS should amalgamate and coordinate the entire
process of data centralization, quality control, manage-
ment, analysis and dissemination. It should allow public
access to data, and also allow regulated but open access by
the scientific community and other stakeholders to these
data. In order to work as efficiently as possible, ECIS activ-
ities should combine the existing resources and experience
of the European Institutions already involved in cancer in-
formation and data dissemination, most of which already
have the knowledge, skills and instruments to carry out
the main tasks required.
The Joint Research Centre (JRC), the European Com-
mission in-house science service, would be the most ap-
propriate to take on the task of hosting and managing
the central data repository. ENCR could play a crucial
role in maintaining a close connection between the ECIS
activities and those of the participating cancer registries.
IARC should continue to exercise the function of ac-
creditation of cancer registries, training and provision of
comparable cancer information at the global level. A
network of European scientific institutions (such as
those involved in EUROCARE or EUROCOURSE) is the
most appropriate organizational structure to carry outthe activities of data quality control, analysis, diffusion
and dissemination in an efficient way [6].
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